<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01435213</url>
  </required_header>
  <id_info>
    <org_study_id>3099002</org_study_id>
    <nct_id>NCT01435213</nct_id>
  </id_info>
  <brief_title>Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline</brief_title>
  <acronym>AIMI</acronym>
  <official_title>Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline - a PET Study in Healthy Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turku</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Turku</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to validate [11C]ORM-13070 as an alpha2C-adrenoceptor imaging
      agent for human positron emission tomography (PET) studies of brain alpha2C-adrenoceptor
      occupancy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Receptor occupancy</measure>
    <time_frame>30 minutes</time_frame>
    <description>PET tracer (interventional drug) uptake in the brain is measured for 30 minutes by PET after various pharmacological and physiological pre-treatments.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Atipamezole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atomoxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin-induced hypoglycemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cold pressor test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atipamezole</intervention_name>
    <description>Administration of a single dose of 5-150 micrograms of atipamezole as an intravenous infusion</description>
    <arm_group_label>Atipamezole</arm_group_label>
    <other_name>ANTISEDAN VET</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atomoxetine</intervention_name>
    <description>A single dose of 1.2 mg/kg of atomoxetine administered orally</description>
    <arm_group_label>Atomoxetine</arm_group_label>
    <other_name>Strattera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>A single dose of ketamine (approximately 60 mg) administered as an intravenous infusion</description>
    <arm_group_label>Ketamine</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cold pressor test</intervention_name>
    <description>30-45 min cold pressor test of the foot</description>
    <arm_group_label>Cold pressor test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Insulin administered as an intravenous infusion to induce hypoglycemia</description>
    <arm_group_label>Insulin-induced hypoglycemia</arm_group_label>
    <other_name>Insulin Actrapid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A single dose of placebo (capsules) administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent (IC) obtained.

          -  Good general health ascertained by detailed medical history, laboratory investigations
             and physical examination.

          -  Males between 20 and 40 years of age (inclusive).

          -  Body mass index (BMI) between 18-28 kg/m2 inclusive (BMI = weight/height2).

          -  Weight 60-100 kg (inclusive).

        Exclusion Criteria:

          -  Suspected poor compliance with the protocol or inability to communicate well with the
             study personnel.

          -  Veins unsuitable for repeated venipuncture.

          -  CYP2D6 slow metabolizer or ultrarapid metabolizer genotype.

          -  Evidence of clinically significant cardiovascular, renal, hepatic, haematological,
             gastrointestinal, pulmonary, metabolic-endocrine, neurological, urogenital or
             psychiatric disease as judged by the investigator.

          -  Any condition requiring regular concomitant medication including herbal products or
             likely to need any concomitant medication during the study.

          -  Susceptibility to severe allergic reactions.

          -  Intake of any medication that could affect the outcome of the study, within 2 weeks
             prior to the tracer administration (2 months for enzyme inducing drugs like rifampicin
             or carbamazepine), or less than 5 times the half-life of the medication.

          -  Regular consumption of more than 21 units of alcohol per week (1 unit = 4 cl spirits,
             about 13 g of alcohol).

          -  Current use of nicotine-containing products more than 5 cigarettes or equivalent/day.

          -  Inability to refrain from using nicotine-containing products during the stay at the
             study centre.

          -  Inability to refrain from consuming caffeine-containing beverages during the stay at
             the study centre, e.g. propensity for headache when refraining from
             caffeine-containing beverages.

          -  Blood donation or loss of significant amount of blood within 2 months prior to the
             screening visit.

          -  Abnormal 12-lead electrocardiogram (ECG) finding of clinical relevance after 10
             minutes rest in supine position at the screening visit, for example:

          -  QTc (calculated using Bazett's formula) &gt; 450 msec,

          -  PR &lt; 120 msec or &gt; 210 msec,

          -  QRS &lt; 70 msec or &gt; 120 msec.

          -  Heart rate (HR) &lt; 40 beats/minute or &gt; 90 beats/minute after 10 minutes rest in supine
             position at the screening visit.

          -  At the screening visit, systolic blood pressure (BP) &lt; 90 mmHg or &gt; 140 mmHg after 10
             minutes in supine position, diastolic BP &lt; 50 mmHg or &gt; 90 mmHg after 10 minutes in
             supine position.

          -  Any abnormal laboratory value, vital sign or physical examination result, which may in
             the opinion of the investigator interfere with the interpretation of the test results
             or cause a health risk to the subject if he takes part in the study.

          -  History of drug abuse or positive result in drug abuse test.

          -  Positive serology to human immunodeficiency virus antibodies (HIVAb), hepatitis B
             surface antigen (HBsAg) or hepatitis C virus antibodies (HCVAb).

          -  Anatomical abnormality in brain MRI which may in the opinion of the investigator
             interfere with the interpretation of the PET results.

          -  Any other condition that in the opinion of the investigator would interfere with the
             evaluation of the results or constitute a health risk to the subject.

          -  Participation in another clinical drug study within 3 months prior to this study.

          -  Participation in a prior PET study or other medical or occupational exposure to
             significant doses of ionizing radiation.

          -  Any contraindication to MRI of the brain.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juha Rinne, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Turku</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Turku, Clinical Research Services Turku CRST</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Turku, Turku PET Centre</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <link>
    <url>http://www.crst.fi</url>
    <description>Clinical Research Services Turku CRST</description>
  </link>
  <link>
    <url>http://www.turkupetcentre.fi/</url>
    <description>Turku PET Centre</description>
  </link>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2011</study_first_submitted>
  <study_first_submitted_qc>September 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2011</study_first_posted>
  <last_update_submitted>February 15, 2013</last_update_submitted>
  <last_update_submitted_qc>February 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Turku</investigator_affiliation>
    <investigator_full_name>Juha Rinne</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>alpha2-adrenoceptor</keyword>
  <keyword>receptor occupancy</keyword>
  <keyword>positron emission tomography</keyword>
  <keyword>[11C]ORM-13070</keyword>
  <keyword>striatum</keyword>
  <keyword>brain</keyword>
  <keyword>noradrenaline</keyword>
  <keyword>norepinephrine</keyword>
  <keyword>endogenous</keyword>
  <keyword>binding</keyword>
  <keyword>Validation studies</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Atipamezole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

